AbbVie California
Pharmalot

AbbVie is reprimanded by the FDA for failing to properly probe death complaints

By Ed Silverman

Valeant Addyi
Pharmalot

The Addyi female libido pill has fewer restrictions in Canada. Is the U.S. next?

By Ed Silverman

Pharmalot
Pharmalot

A tip from the FDA: don’t use the same equipment to make drugs and pesticides

By Ed Silverman

Pharmalot

Pharmalittle: Shire rejects latest Takeda offer; Greek parliament ends Novartis bribery probe

By Ed Silverman

STAT Plus panel
Biotech

Why are some of New York’s top investors bullish on biotech? The science is getting better

By Adam Feuerstein

Compounding Pharmacy
Pharmalot

FDA moves to address disputes between drug makers and compounders

By Ed Silverman

Pharmalot

Pharmalittle: CVS taps an Eli Lilly exec to run its PBM; Glaxo pharma chief cuts his budget

By Ed Silverman

Patient Advocacy Funding
Pharmalot

Millions in fines are adding up as clinical trial information goes unreported

By Ed Silverman

Pharmalot

Pharmalittle: Glaxo wins a reprieve for Advair; AstraZeneca delays lung cancer trial results

By Ed Silverman

Sarepta
Biotech

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

By Adam Feuerstein

Mail bag
Biotech

You have questions on genome-editing. We have answers

By Adam Feuerstein and Sharon Begley

Pharmalot

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

By Ed Silverman

Peanuts
Biotech

Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment

By Adam Feuerstein

Alzheimer's brain illustration - Loss of connection between cells
Pharmalot

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

By Ed Silverman

Pharmalot

Pharmalittle: FDA tries to boost Alzheimer drug development; Roche bets $1.9 billion on cancer data firm

By Ed Silverman

Pharmalot

Pharmalittle: Greek probe into Novartis bribes widens; Philippines agency sues Sanofi over dengue vaccine

By Ed Silverman

Biotech

New paper raises safety concerns about neuro gene therapy, stocks slide

By Adam Feuerstein

Eye - for spark
Biotech

FDA approves first gene therapy targeting rare form of inherited blindness

By Adam Feuerstein

Pharmalot

Sales of antibiotics used in food-producing livestock unexpectedly dropped

By Ed Silverman

Pharmalot

Pharmalittle: Amazon talks to generic drug makers; FDA to speed cancer drug approvals

By Ed Silverman

Lung cancer scans
Business

Roche reshuffles lung cancer immunotherapy market with positive clinical trial results

By Adam Feuerstein

Cytokinetics
Biotech

7 things to know before Cytokinetics announces results from a pivotal drug study in ALS

By Adam Feuerstein

Pharmalot

Pharmalittle: Astellas is probed for patient support; Trump replenishes the swamp

By Ed Silverman

Adam's Take

Here’s why investors in Geron, Puma Bio, Intrexon, and Ziopharm should worry

By Adam Feuerstein

Pharmalot

Pharmalittle: Trump to name former Lilly exec to run HHS; Gottlieb tells pharma to end ‘shenanigans’

By Ed Silverman

Medication vials
Pharmalot

Waste not, want not: A new bill tries to reduce waste caused by drug makers

By Ed Silverman

Pharmalot

Pharmalittle: Novo blasts U.S. transparency bills; House hearing set for patents and sovereign immunity

By Ed Silverman

Adam's Take

The case for approving DBV’s peanut allergy vaccine; Celgene, Trump, and serial drug price hikes

By Adam Feuerstein

Adam's Take

Spark Therapeutics’s success is lifting all gene therapy stocks even though risks remain

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy